mucin 1

mucin 1

A 265- to 400-kD transmembrane glycoprotein encoded by MUC1 on chromosome 1q21, which is found in milk-fat-globule membranes.

Normal expression
Normal epithelia and perineurial cells, choroid plexus, arachnoid granulation, epithelioid histiocytes.

Abnormal expression
Neoplastic epithelia, meningiomas, mesotheliomas, mesenchymal tumours, some lymphomas, anaplastic large cell lymphomas.
References in periodicals archive ?
Both firm's products target an abnormal form of the autologous cell surface-associated protein, Mucin 1 (MUC1), which is over-expressed in the majority of known tumour types.
The method of use claims secured in patent number 5192020 entitled Use of mannose receptor-bearing antigen presenting cells for the manufacture of medicament for eliciting cytotoxic T cell response to antigen provide for the treatment of patients with dendritic cells that have been pulsed with mannan fusion protein (M-FP) conjugated to an antigen, including but not limited to mucin 1.
Inflammation driven by overexpression of the hypoglycosylated abnormal mucin 1 (MUC1) links inflammatory bowel disease and pancreatitis.
This US patent grant protects the method of composition and the method of use of CVac, which is formulated in a patient's own dendritic cells and then reinjected back into the patient to generate a cytotoxic T cell response against the mucin 1 antigen.
CVac is a personalised immunotherapy composed of a patient's own dendritic cells pulsed with the cancer antigen mucin 1, conjugated to oxidised mannan.
According to the company, the application protects the method of composition and method of use of its CVac for the generation of a cytotoxic T cell response against the mucin 1 antigen.
According to the company, the claims secured in patent number 5192020 provide for the treatment of patients with dendritic cells that have been pulsed with mannan fusion protein (M-FP) conjugated to an antigen, including but not limited to mucin 1.
This CANcer VAccine Study (CANVAS) is reportedly a multi-centre, randomised, placebo-controlled study of CVac in mucin 1 positive, epithelial ovarian cancer patients who have undergone optimal surgery and achieve complete remission after first-line chemotherapy.